The purpose of the IBC is to ensure that the NIH Guidelines for Research Involving Recombinant DNA Molecules are adhered to at FIU. Recombinant DNA molecules are defined by NIH guidelines as either: (i) molecules that are constructed outside living cells by joining natural or synthetic DNA segments to DNA molecules that can replicate in a living cell, or (ii) molecules that result from the replication of those described in (i) above. See the section "Definition of Recombinant DNA Molecules" for further detail.
FIU requires that all use of recombinant DNA at the University be registered with the Institutional Biosafety Committee, even if the use is as simple as the cloning of allelic PCR products prior to sequencing. In many cases this process will be as simple as filling out a form indicating that the type of recombinant work being carried out in your lab is exempt from NIH guidelines.
This site contains the necessary tools and information to assist investigators during the IBC protocol submission and review process. You can find them on the left navigation menu including Obtaining IBC Approval which provides step by step instructions on preparing your submission, Policies & Procedures which contains helpful resources on conducting research with Recombinant DNA, and IBC FAQs which contains answers to commonly asked questions.
New IBC Online Training Requirements (Effective June 1, 2013)
The Office of Research Integrity (ORI) is responsible for the ethical and regulatory oversight of research at Florida International University that involves Recombinant DNA. ORI supports and oversees the work of the Institutional Biosafety Committee (IBC).
The IBC Chairperson is Kathleen Rein and can be reached at: (305) 348-6682